{
    "xml": "<topic id=\"PHP5807\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/octreotide\" basename=\"octreotide\" title=\"OCTREOTIDE\">\n<title>OCTREOTIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_584\" namespace=\"/interactions/list-of-drug-interactions/hormone-antagonists/octreotide\">Octreotide</xref>\n</p>\n<data name=\"vtmid\">126155003</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_946978684\" title=\"Somatostatin analogues\">Somatostatin analogues</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34576\" title=\"SOMATOSTATIN ANALOGUES\" namespace=\"/drug-classes/somatostatin-analogues\">SOMATOSTATIN ANALOGUES</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n<data name=\"secondaryDomainsOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP64953\" outputclass=\"indicationsAndDose\" rev=\"1.49\" parent=\"/drugs/octreotide\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Symptoms associated with carcinoid tumours with features of carcinoid syndrome, VIPomas, glucagonomas</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 50&#8239;micrograms 1&#8211;2 times a day, adjusted according to response; increased to 200&#8239;micrograms 3 times a day, higher doses may be required exceptionally; maintenance doses are variable, in carcinoid tumours, discontinue after 1 week if no effect, initial dose may be given by intravenous injection (with ECG monitoring), if rapid response required.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Acromegaly, short-term treatment before pituitary surgery or long-term treatment in those inadequately controlled by other treatment or until radiotherapy becomes fully effective</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>100&#8211;200&#8239;micrograms 3 times a day, discontinue if no improvement within 3 months.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention of complications following pancreatic surgery</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Test dose before use of depot preparation</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Test dose 50&#8211;100&#8239;micrograms for 1 dose, test dose should be given if subcutanous octreotide not previously given.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Acromegaly</p>\n<p outputclass=\"therapeuticIndication\">Neuroendocrine (particularly carcinoid) tumour adequately controlled by subcutaneous octreotide</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By deep intramuscular injection using depot injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 20&#8239;mg every 4&#8239;weeks for 3 months then adjusted according to response, increased if necessary up to 30&#8239;mg every 4&#8239;weeks, to be administered into the gluteal muscle, for <i>acromegaly</i>, start depot 1 day after the last dose of subcutaneous octreotide, for <i>neuroendocrine tumours</i>, continue subcutaneous octreotide for 2 weeks after first dose of depot octreotide.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Advanced neuroendocrine tumours of the midgut, or tumours of unknown primary origin where non-midgut sites of origin have been excluded</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By deep intramuscular injection using depot injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>30&#8239;mg every 4&#8239;weeks.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Reduce intestinal secretions in palliative care</p>\n<p outputclass=\"therapeuticIndication\">Reduce vomiting due to bowel obstruction in palliative care</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By continuous subcutaneous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>0.25&#8211;0.5&#8239;mg/24 hours (max. per dose 0.75&#8239;mg/24 hours), occasionally doses higher than the maximum are sometimes required.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64943\" outputclass=\"interactions\" rev=\"1.11\" parent=\"/drugs/octreotide\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (octreotide).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64910\" outputclass=\"sideEffects\" rev=\"1.24\" parent=\"/drugs/octreotide\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">arrhythmias</ph>; <ph outputclass=\"sideEffect\">biliary colic (associated with abrupt withdrawal of subcutaneous octreotide)</ph>; <ph outputclass=\"sideEffect\">bradycardia</ph>; <ph outputclass=\"sideEffect\">dehydration</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">dyspnoea</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hepatitis</ph>; <ph outputclass=\"sideEffect\">pancreatitis (associated with abrupt withdrawal of subcutaneous octreotide)</ph>; <ph outputclass=\"sideEffect\">rash</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Gastro-intestinal side-effects</p>\n<p>Administering non-depot injections of octreotide between meals and at bedtime may reduce gastro-intestinal side-effects.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65034\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/octreotide\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Effective contraception required during treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64936\" outputclass=\"pregnancy\" parent=\"/drugs/octreotide\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Possible effect on fetal growth; manufacturer advises use only if potential benefit outweighs risk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65053\" outputclass=\"breastFeeding\" parent=\"/drugs/octreotide\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;present in milk in <i>animal </i>studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64977\" outputclass=\"hepaticImpairment\" parent=\"/drugs/octreotide\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Adjustment of maintenance dose of non-depot preparations may be necessary in patients with liver cirrhosis.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64882\" outputclass=\"monitoringRequirements\" parent=\"/drugs/octreotide\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>ECG monitoring required with intravenous administration.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Monitor thyroid function on long-term therapy.</p>\n<p>Monitor liver function.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64893\" outputclass=\"treatmentCessation\" rev=\"1.18\" parent=\"/drugs/octreotide\">\n<title>Treatment cessation</title>\n<body>\n<section>\n<sectiondiv>\n<p>Avoid abrupt withdrawal of short-acting subcutaneous octreotide (associated with biliary colic and pancreatitis).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65073\" outputclass=\"directionsForAdministration\" rev=\"1.22\" parent=\"/drugs/octreotide\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>For <i>intravenous infusion</i>, dilute with Sodium Chloride 0.9% to a concentration of 10&#8211;50%.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP5807-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/octreotide\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74977\" title=\"Solution for injection\" namespace=\"/drugs/octreotide/solution-for-injection\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74971\" title=\"Powder and solvent for suspension for injection\" namespace=\"/drugs/octreotide/powder-and-solvent-for-suspension-for-injection\">Powder and solvent for suspension for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107735\" namespace=\"/guidance/prescribing-in-palliative-care\" title=\"Prescribing in palliative care\" count=\"1\" rel=\"backlink\">Prescribing in palliative care</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78299\" namespace=\"/treatment-summaries/dopamine-receptor-agonists\" title=\"Dopamine-receptor agonists\" count=\"1\" rel=\"backlink\">Dopamine-receptor agonists</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78591\" namespace=\"/treatment-summaries/hormones-malignant-disease\" title=\"Hormones, malignant disease\" count=\"5\" rel=\"backlink\">Hormones, malignant disease</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_584\" namespace=\"/interactions/list-of-drug-interactions/hormone-antagonists/octreotide\" title=\"Octreotide\" count=\"1\" rel=\"link\">Octreotide</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34576\" namespace=\"/drug-classes/somatostatin-analogues\" title=\"SOMATOSTATIN ANALOGUES\" count=\"1\" rel=\"link\">SOMATOSTATIN ANALOGUES</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74977\" namespace=\"/drugs/octreotide/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74971\" namespace=\"/drugs/octreotide/powder-and-solvent-for-suspension-for-injection\" title=\"Powder and solvent for suspension for injection\" count=\"1\" rel=\"link\">Powder and solvent for suspension for injection</xref>\n</links>\n</topic>",
    "id": "PHP5807",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/octreotide",
    "basename": "octreotide",
    "title": "OCTREOTIDE",
    "interactants": [
        {
            "id": "bnf_int_584",
            "label": "Octreotide"
        }
    ],
    "vtmid": "126155003",
    "drugClassification": [
        "Somatostatin analogues"
    ],
    "inheritsFromClass": [
        "SOMATOSTATIN ANALOGUES"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "secondaryDomainsOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Symptoms associated with carcinoid tumours with features of carcinoid syndrome, VIPomas, glucagonomas",
                        "html": "Symptoms associated with carcinoid tumours with features of carcinoid syndrome, VIPomas, glucagonomas"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 50 micrograms 1&#8211;2 times a day, adjusted according to response; increased to 200 micrograms 3 times a day, higher doses may be required exceptionally; maintenance doses are variable, in carcinoid tumours, discontinue after 1 week if no effect, initial dose may be given by intravenous injection (with ECG monitoring), if rapid response required.",
                        "html": "<p>Initially 50&#8239;micrograms 1&#8211;2 times a day, adjusted according to response; increased to 200&#8239;micrograms 3 times a day, higher doses may be required exceptionally; maintenance doses are variable, in carcinoid tumours, discontinue after 1 week if no effect, initial dose may be given by intravenous injection (with ECG monitoring), if rapid response required.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Acromegaly, short-term treatment before pituitary surgery or long-term treatment in those inadequately controlled by other treatment or until radiotherapy becomes fully effective",
                        "html": "Acromegaly, short-term treatment before pituitary surgery or long-term treatment in those inadequately controlled by other treatment or until radiotherapy becomes fully effective"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "100&#8211;200 micrograms 3 times a day, discontinue if no improvement within 3 months.",
                        "html": "<p>100&#8211;200&#8239;micrograms 3 times a day, discontinue if no improvement within 3 months.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prevention of complications following pancreatic surgery",
                        "html": "Prevention of complications following pancreatic surgery"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature).",
                        "html": "<p>(consult product literature).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Test dose before use of depot preparation",
                        "html": "Test dose before use of depot preparation"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "Test dose 50&#8211;100 micrograms for 1 dose, test dose should be given if subcutanous octreotide not previously given.",
                        "html": "<p>Test dose 50&#8211;100&#8239;micrograms for 1 dose, test dose should be given if subcutanous octreotide not previously given.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Acromegaly",
                        "html": "Acromegaly"
                    },
                    {
                        "textContent": "Neuroendocrine (particularly carcinoid) tumour adequately controlled by subcutaneous octreotide",
                        "html": "Neuroendocrine (particularly carcinoid) tumour adequately controlled by subcutaneous octreotide"
                    }
                ],
                "specificity": {
                    "routes": [
                        "deep intramuscular injection using depot injection"
                    ],
                    "textContent": "By deep intramuscular injection using depot injection",
                    "html": "By deep intramuscular injection using depot injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 20 mg every 4 weeks for 3 months then adjusted according to response, increased if necessary up to 30 mg every 4 weeks, to be administered into the gluteal muscle, for acromegaly, start depot 1 day after the last dose of subcutaneous octreotide, for neuroendocrine tumours, continue subcutaneous octreotide for 2 weeks after first dose of depot octreotide.",
                        "html": "<p>Initially 20&#8239;mg every 4&#8239;weeks for 3 months then adjusted according to response, increased if necessary up to 30&#8239;mg every 4&#8239;weeks, to be administered into the gluteal muscle, for <i>acromegaly</i>, start depot 1 day after the last dose of subcutaneous octreotide, for <i>neuroendocrine tumours</i>, continue subcutaneous octreotide for 2 weeks after first dose of depot octreotide.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Advanced neuroendocrine tumours of the midgut, or tumours of unknown primary origin where non-midgut sites of origin have been excluded",
                        "html": "Advanced neuroendocrine tumours of the midgut, or tumours of unknown primary origin where non-midgut sites of origin have been excluded"
                    }
                ],
                "specificity": {
                    "routes": [
                        "deep intramuscular injection using depot injection"
                    ],
                    "textContent": "By deep intramuscular injection using depot injection",
                    "html": "By deep intramuscular injection using depot injection"
                },
                "adult": [
                    {
                        "textContent": "30 mg every 4 weeks.",
                        "html": "<p>30&#8239;mg every 4&#8239;weeks.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Reduce intestinal secretions in palliative care",
                        "html": "Reduce intestinal secretions in palliative care"
                    },
                    {
                        "textContent": "Reduce vomiting due to bowel obstruction in palliative care",
                        "html": "Reduce vomiting due to bowel obstruction in palliative care"
                    }
                ],
                "specificity": {
                    "routes": [
                        "continuous subcutaneous infusion"
                    ],
                    "textContent": "By continuous subcutaneous infusion",
                    "html": "By continuous subcutaneous infusion"
                },
                "adult": [
                    {
                        "textContent": "0.25&#8211;0.5 mg/24 hours (max. per dose 0.75 mg/24 hours), occasionally doses higher than the maximum are sometimes required.",
                        "html": "<p>0.25&#8211;0.5&#8239;mg/24 hours (max. per dose 0.75&#8239;mg/24 hours), occasionally doses higher than the maximum are sometimes required.</p>"
                    }
                ]
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (octreotide).",
                "html": "<p>Appendix 1 (octreotide).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "arrhythmias",
                        "html": "arrhythmias",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "biliary colic (associated with abrupt withdrawal of subcutaneous octreotide)",
                        "html": "biliary colic (associated with abrupt withdrawal of subcutaneous octreotide)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bradycardia",
                        "html": "bradycardia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dehydration",
                        "html": "dehydration",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dyspnoea",
                        "html": "dyspnoea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hepatitis",
                        "html": "hepatitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pancreatitis (associated with abrupt withdrawal of subcutaneous octreotide)",
                        "html": "pancreatitis (associated with abrupt withdrawal of subcutaneous octreotide)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Gastro-intestinal side-effects",
                "textContent": "Administering non-depot injections of octreotide between meals and at bedtime may reduce gastro-intestinal side-effects.",
                "html": "<p>Administering non-depot injections of octreotide between meals and at bedtime may reduce gastro-intestinal side-effects.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Effective contraception required during treatment.",
                "html": "<p>Effective contraception required during treatment.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Possible effect on fetal growth; manufacturer advises use only if potential benefit outweighs risk.",
                "html": "<p>Possible effect on fetal growth; manufacturer advises use only if potential benefit outweighs risk.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;present in milk in animal studies.",
                "html": "<p>Manufacturer advises avoid&#8212;present in milk in <i>animal </i>studies.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Adjustment of maintenance dose of non-depot preparations may be necessary in patients with liver cirrhosis.",
                "html": "<p>Adjustment of maintenance dose of non-depot preparations may be necessary in patients with liver cirrhosis.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "ECG monitoring required with intravenous administration.",
                "html": "<p>ECG monitoring required with intravenous administration.</p>"
            },
            {
                "type": "patientParameters",
                "textContent": "Monitor thyroid function on long-term therapy.\n\nMonitor liver function.",
                "html": "<p>Monitor thyroid function on long-term therapy.</p><p>Monitor liver function.</p>"
            }
        ]
    },
    "treatmentCessation": {
        "treatmentCessation": [
            {
                "type": "treatmentCessation",
                "textContent": "Avoid abrupt withdrawal of short-acting subcutaneous octreotide (associated with biliary colic and pancreatitis).",
                "html": "<p>Avoid abrupt withdrawal of short-acting subcutaneous octreotide (associated with biliary colic and pancreatitis).</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "For intravenous infusion, dilute with Sodium Chloride 0.9% to a concentration of 10&#8211;50%.",
                "html": "<p>For <i>intravenous infusion</i>, dilute with Sodium Chloride 0.9% to a concentration of 10&#8211;50%.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74977",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74971",
                "label": "Powder and solvent for suspension for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP107735",
                "label": "Prescribing in palliative care",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78299",
                "label": "Dopamine-receptor agonists",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78591",
                "label": "Hormones, malignant disease",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_584",
                "label": "Octreotide",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34576",
                "label": "SOMATOSTATIN ANALOGUES",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74977",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74971",
                "label": "Powder and solvent for suspension for injection",
                "type": "medicinalForm"
            }
        ]
    }
}